膀胱腫瘍に対する膀胱保存手術後の1-hexylcarbamoyl-5-fluorouracil (HCFU)およびHCFUと2,5-di-0-acetyl-D-glucaro(1-4)(6-3)dilactone (SLA)の再発予防効果の検討

Abstract

膀胱保存手術後の術後再発予防に対するHCFUの効果およびHCFUとSLAの併用効果を検討した.1) 57例の膀胱手術後の再発は1年2例, 2年15例であった.2) 87例を対象として, 封筒法にてHCFUおよびSLA併用群とHCFU単独群での再発予防効果は, 1年以上で併用群で成績が良好であった.3)副作用は11例にみられたが, 重篤な副作用は1例もなかった

To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out. We studied the effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU), and the effects of the combination of HCFU and 2.5-di-O-acetyl-D-glucaro-(1-4)(6-3) dilactone (SLA) which is an anti-beta-glucuronidase agent, for preventive therapy. In the patients treated with HCFU, the recurrence rate was 3.6% and 26.6% one year and two years, respectively, after conservative operation. In the patients treated with both SLA and HCFU, the recurrence rate was lower than in those treated with HCFU one year or more after conservative operation, and a long-term preventive effect was expected for nondrinkers.